On November 1, the opening ceremony of Porton Biologics’ Gene and Cell Therapy CDMO Platform was held in Suzhou, China.

Committed to building an end-to-end gene and cell therapy CDMO service platform, Porton Biologics has finished phase one construction of the project. R&D labs of 1200 square meters and GMP workshops of 4000 square meters have all been put into use, providing CDMO services—plasmid, viral vector and cell therapy—from process development to clinical GMP production.

Founded in 2018, Suzhou Porton Biologics Ltd. is located in Suzhou Industrial Park. As a subsidiary of Porton Pharma Solutions Ltd., Porton Biologics has built a CDMO platform providing plasmids, viral vectors and cell therapy products from early studies, investigator-initiated clinical trials, IND filing, clinical trial to commercial production in order to advance drugs into clinical practice and beyond.